Delivery Order SPE2DB22D2005-SPE2DB25FJRC8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a $6,749.06 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30. The order, with an ultimate completion date of August 6, 2025, will be performed at the contractor's Conshohocken, Pennsylvania facility. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count supply) with a ceiling value of $2,320.65. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with a contract ceiling value of $2,831.66. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion on July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package, with a ceiling value of $1,726.44. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, represents a continuation of AmerisourceBergen's pharmaceutical supply role under its larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract does not carry a set-aside...
- The Defense Logistics Agency awarded a $12,553.34 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 tablets. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $2,181.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This competitive, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $2,359.95 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 tablets. The contract employs firm fixed pricing with a completion date of July 24, 2025, and carries no set-aside designation, indicating it was awarded through open competition. Performance will be executed from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $68,595.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count units) on August 5, 2025, with completion required by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJRC8Delivery Order
The Defense Logistics Agency awarded a $5,719.19 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30. The contract is firm fixed price with no set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a single transaction under AmerisourceBergen's broader federal pharmaceutical supply relationship. This award is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal procurement portfolio demonstrates consistent capability to fulfill competitive pharmaceutical supply requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems across multiple therapeutic domains through firm fixed-price delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 8/8/25 |